| Dr Jonathan D Kaplan, OD | |
|
2 Dexter St, Pawtucket, RI 02860-2926 | |
| (401) 723-9540 | |
| (401) 725-6583 |
| Full Name | Dr Jonathan D Kaplan |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 34 Years |
| Location | 2 Dexter St, Pawtucket, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023077898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODTG00494 (Rhode Island) | Primary |
| Provider Name | The Eyeglass Store Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1437290889 PECOS PAC ID: 9931234986 Enrollment ID: O20100317000057 |
News Archive
Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.
The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.
The International HIV/AIDS Alliance recently launched a three-year program in Uganda to expand the role of networks of HIV-positive people in an effort to improve the delivery of services and reduce stigma, Uganda's Monitor reports.
› Verified 2 days ago
| Provider Name | Aeg Rhode Island Professional Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1730898263 PECOS PAC ID: 3870966369 Enrollment ID: O20230303000711 |
News Archive
Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.
The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.
The International HIV/AIDS Alliance recently launched a three-year program in Uganda to expand the role of networks of HIV-positive people in an effort to improve the delivery of services and reduce stigma, Uganda's Monitor reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan D Kaplan, OD 2 Dexter St, Pawtucket, RI 02860-2926 Ph: (401) 723-9540 | Dr Jonathan D Kaplan, OD 2 Dexter St, Pawtucket, RI 02860-2926 Ph: (401) 723-9540 |
News Archive
Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.
The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.
The International HIV/AIDS Alliance recently launched a three-year program in Uganda to expand the role of networks of HIV-positive people in an effort to improve the delivery of services and reduce stigma, Uganda's Monitor reports.
› Verified 2 days ago
Dr. Benjamin D Klibanoff, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 55 Broad St, Pawtucket, RI 02860 Phone: 401-723-3400 | |
Dr. Kenneth A Kaplan, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2 Dexter St, Pawtucket, RI 02860 Phone: 401-723-9540 Fax: 401-725-6583 | |
Glenn S. Prescod, M.d., M.p.h., Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 333 School St, Suite 301, Pawtucket, RI 02860 Phone: 401-725-3600 Fax: 401-728-8760 | |
Modern Eyes Llc Optometrist Medicare: Medicare Enrolled Practice Location: 145 Newport Ave, Pawtucket, RI 02861 Phone: 401-524-4025 | |
David Klibanoff, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 121 Broad St, Pawtucket, RI 02860 Phone: 401-723-3400 Fax: 401-727-2326 | |
Dr. Peter J Liberto, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 145 Newport Ave, Pawtucket, RI 02861 Phone: 401-729-0200 Fax: 401-729-0222 |